BioForest
Filter News
Found 20,000 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
In its announcement, the company did not specify why Kawas’ doctoral research was under investigation, only saying it did not intend to comment on the issue until it had been resolved.
-
BioSpace Movers & Shakers, June 18
6/18/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Nautilus Biotechnology Appoints Emma Lundberg, Ph.D., to Scientific Advisory Board
6/17/2021
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the appointment of Emma Lundberg, Ph.D. to its Scientific Advisory Board.
-
Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company
6/17/2021
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced that Mark Litton, PhD, MBA, in his capacity as Chief Operating Officer, has assumed day-to-day leadership responsibilities for the Company, effective immediately.
-
Pattern Computer Develops Accurate 15-Second COVID-19 Test
6/17/2021
Pattern Computer,® Inc. has developed a novel test for near real-time diagnosis of SARS-CoV-2 infections.
-
Accolade to Announce Fiscal First Quarter 2022 Financial Results
6/17/2021
Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, today announced that it will release fiscal first quarter 2022 financial results on Thursday, July 8, 2021, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
-
Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.
-
Lumen Bioscience and Novo Nordisk Enter into Research Collaboration to Explore Novel Strategies to Deliver Oral Biologics for Cardiometabolic Disease
6/16/2021
Lumen Bioscience announced today it has entered into a research collaboration with Novo Nordisk to evaluate the use of Lumen's unique drug development and manufacturing platform in Novo Nordisk's research and development activities within obesity and other metabolic disorders.
-
Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference
6/16/2021
Impel NeuroPharma today announced that the Company will present a corporate overview at the Raymond James Human Health Innovations Conference on Wednesday, June 23, 2021 at 3:20 p.m. ET.
-
Arnaud Lacoste Is Named Chief Scientific Officer of Aurion Biotech
6/15/2021
Arnaud Lacoste, MBA, PhD, has been named chief scientific officer of Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies.
-
Phase Genomics Releases Platform for Discovering New Viruses in Microbiome Samples
6/15/2021
Phase Genomics, the global leader in proximity-ligation based genomic solutions, today announced the launch of a new platform aimed at the discovery of viral genomes from complex microbiome samples.
-
Visus Therapeutics Announces Executive Leadership Appointments in Operations, Research, Clinical Operations and Intellectual Property
6/15/2021
Visus Therapeutics Inc. today announced the appointment of six new senior leaders.
-
Lightspeed Microscopy, Inc. raises $4M in Series A Financing Round with Plans to Revolutionize Pathology
6/15/2021
Lightspeed Microscopy, Inc., an end-to-end 3D pathology platform, announced today it has raised $4 million in a Series A financing round.
-
Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the Clinic
6/15/2021
Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, announced the completion of an oversubscribed $210 million Series B financing.
-
NanoString and Parker Institute for Cancer Immunotherapy Collaborate to Optimize Cell Therapies to Treat Cancer
6/15/2021
NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, and the Parker Institute for Cancer Immunotherapy announced that they are collaborating on an expansive molecular characterization project for cellular therapies.
-
Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference
6/15/2021
Silverback Therapeutics, Inc. today announced that the Company will participate in the Raymond James Human Health Innovation Conference.
-
Clinical Catch-Up: June 7-11
6/14/2021
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more. -
Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants
6/14/2021
Cocrystal Pharma, Inc. announces that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent SARS-CoV-2 variants.
-
AbSci Announces Acquisition of Target Discovery Company Totient
6/14/2021
AbSci today announced the acquisition of Totient, a discovery company harnessing human immune responses to identify novel antibodies and their therapeutic targets.